Oxford Nanopore Technologies Plc (Oxford Nanopore) develops and sells nanopore sequencing products for electronic analysis of single molecules. The company serves industries including scientific research, healthcare, and industrial applications by providing sequencing solutions that offer real-time analysis and scalability from small to large-scale projects. The company markets its products through Oxford Nanopore Technologies, the Wheel icon, AmPORE-TB, EPI2ME, GridION, MinION, MinKNOW, PromethION, P2 Solo, and P2 brand names.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Oxford Nanopore has undertaken several R&D initiatives to align with its commercial strategy. The company has prioritized R&D efforts and refined its product portfolio to focus on platforms that best serve priority end markets, are fit for Oxford Nanopore Technologies, and offer scalable commercial opportunities. The company is adopting formal process improvements to enable repeatable success. For 2026, the company is focusing on progressing Q-line and high throughput FC, targeting high-priority segments within DNA & RNA, while also developing protein capability and advancing its regulated portfolio for applied markets. Oxford Nanopore has a broad patent portfolio, with more than 2,500 issued patents and patent applications in over 250 patent families. These patents cover various aspects of nanopore sensing, including fundamental patents for nanopore sensing and DNA-sequencing. The company is developing a platform technology adaptable with various nanopore sensors for analyzing different molecules. The company's intellectual property portfolio reflects its broad range of expertise and active R&D projects, supported by research within the laboratories of its academic collaborators. Oxford Nanopore has established major technology alliances with leading research institutions, including Oxford University Innovation, Harvard University, UMASS, Boston University, Texas A&M, University of California, Santa Cruz, Brown University, Cambridge University, Illinois University, Stanford University, VIB and Vrije Universiteit Brussel, KU Leuven, University College of London, University of Michigan, University of Massachusetts, The Ohio State University, Yissum R&D Company of the Hebrew University of Jerusalem, and the University of Southampton. In FY2025, the company spent GBP97.7 million on its R&D activities, which as a percentage of revenue stood at 43.6%.